Use of Partial Area under the Curve Metrics to Assess Bioequivalence of Methylphenidate Multiphasic Modified Release Formulations

Ítems similars

• Survey of International Regulatory Bioequivalence Recommendations for Approval of Generic Topical Dermatological Drug Products
  per: Braddy, April C., et al.
  Publicat: (2014)
• Common Reasons for “For-Cause” Inspections in Bioequivalence Studies Submitted to the Food and Drug Administration
  per: Li, Bing V., et al.
  Publicat: (2012)
• A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH
  per: Zhu, Hao, et al.
  Publicat: (2019)
• Common Deficiencies with Bioequivalence Submissions in Abbreviated New Drug Applications Assessed by FDA
  per: Liu, Qing, et al.
  Publicat: (2011)
• Metrics for the Evaluation of Bioequivalence of Modified-Release Formulations
  per: Endrenyi, Laszlo, et al.
  Publicat: (2012)